Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SYO-1644 vs Nexavar in Healthy Male Volunteers
NCT03674060Phase 1Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer (4 arms), sponsored by Samyang Biopharmaceuticals Corporation. Primary endpoint: Evaluation of pharmacokinetic properties at 168 hours. Started Oct 2018; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)thyroid cancer
Beyond the preview
Go deeper on NCT03674060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674060.